Đánh giá kết quả điều trị phác đồ Atezolizumab kết hợp Bevacizumab trên ung thư biểu mô tế bào gan=Evaluation of treatment results of Atezolizumab combined with Bevacizumab regimen in hepatocellular carcinoma

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Hoa Nguyễn, Văn Huy Nguyễn, Thanh Phương Phạm, Thị Quế Phạm, Thắng Trần, Hồng Thăng Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.271-277

Bộ sưu tập: Metadata

ID: 245963

Thêm vào giỏ

Đánh giá kết quả điều trị và một số tác dụng không mong muốn của phác đồ Atezolizumab-Bevacizumab trên bệnh nhân ung thư biểu mô tế bào gan. Đối tượng và phương pháp nghiên cứu: Nghiên cứu hồi cứu, can thiệp lâm sàng không đối chứng trên 45 bệnh nhân được chẩn đoán ung thư gan nguyên phát, giai đoạn BCLC B không phù hợp hoặc thất bại sau các điều trị tại chỗ, tại vùng hoặc BCLC C, có chỉ định điều trị toàn thân, được điều trị bằng phác đồ Atezolizumab phối hợp Bevacizumab tại Bệnh viện K, từ T5/2020 đến T5/2024. Kết quả: Tỷ lệ đáp ứng là 35,6%, trung vị thời gian sống bệnh không tiến triển 5 tháng và sống thêm toàn bộ đạt 15,5 tháng. Độc tính độ 3, 4 gặp ở 6,7% bệnh nhân gồm tăng huyết áp, tăng men gan và giảm tiểu cầu. Kết luận: Phác đồ Atezolizumab-Bevacizumab cho hiệu quả và dung nạp tốt trên bệnh nhân ung thư biểu mô tế bào gan tại Việt Nam.The treatment results and side effects of Atezolizumab combined with Bevacizumab regimen in patients with hepatocellular carcinoma. Subjects and methods: Retrospective study on 45 patients diagnosed with hepatocellular carcinoma, stage BCLC B was unsuitable or failed after local interventions, BCLC C, treated systemic therapy with Atezolizumab combined with Bevacizumab regimen at K Hospital, from May 2020 to May 2024. Results: The response rate was 35.6%, median progressive-free survival was 5 months and median overall survival was 15.5 months. Grade 3 and 4 toxicities occurred in 6.7% patients including hypertension, increased liver enzymes and thrombocytopenia. Conclusions: Atezolizumab-Bevacizumab regimen is effective and well-tolerated in patients with hepatocellular carcinoma in Vietnam.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR